SELLAS Life Sciences Group, Inc. (SLS)
- Previous Close
1.5100 - Open
1.5400 - Bid 1.1600 x 200
- Ask 2.1300 x 200
- Day's Range
1.5050 - 1.6200 - 52 Week Range
0.7700 - 1.8500 - Volume
2,476,234 - Avg. Volume
1,463,116 - Market Cap (intraday)
151.277M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5000 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.83
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
www.sellaslifesciences.comRecent News: SLS
View More
Performance Overview: SLS
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SLS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLS
View MoreValuation Measures
Market Cap
151.28M
Enterprise Value
138.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
15.98
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-58.79%
Return on Equity (ttm)
-144.90%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-27.13M
Diluted EPS (ttm)
-0.5000
Balance Sheet and Cash Flow
Total Cash (mrq)
28.4M
Total Debt/Equity (mrq)
3.13%
Levered Free Cash Flow (ttm)
-24M